| Active substance | Nintedanib |
| Holder | SCS Boehringer Ingelheim |
| Status | Closed |
| Indication | In combination with docetaxel adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer of adenocarcinoma tumour histology progressing after one prior line of chemotherapy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 30/07/2015 |
Vargatef®
Last updated on 03/04/2024